Ensysce Biosciences Shares Are Trading Higher After the Company Announced FDA Breakthrough Therapy Designation for PF614-MPAR
在Ensysce Biosciences宣布美国食品药品管理局将 PF614-MPAR 指定为突破性疗法后,该公司股价走高
Ensysce Biosciences Shares Are Trading Higher After the Company Announced FDA Breakthrough Therapy Designation for PF614-MPAR
在Ensysce Biosciences宣布美国食品药品管理局将 PF614-MPAR 指定为突破性疗法后,该公司股价走高
使用浏览器的分享功能,分享给你的好友吧